CD8A and neoplasm: These findings align with our results, demonstrating that CD25-biased IL-2cx and ICs can achieve strong antitumor responses with a more favorable safety profile by selectively stimulating recently activated CD8+ T cells in the tumor microenvironment while minimizing harmful systemic inflammatory responses driven by NK cells.54